Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206309 · ClinicalTrials.gov registry record
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
A clinical trial of Graft Vs Host Disease and Bronchiolitis Obliterans, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- 911
- Enrollment target
- 14
- Study locations
NCT01206309 is a study of Graft Vs Host Disease and Bronchiolitis Obliterans that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 911 participants, above the 113-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (706% higher). The trial reports 14 study locations across 12 states.
The verdict
NCT01206309, a study of Graft Vs Host Disease and Bronchiolitis Obliterans, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- 911 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
Conditions Studied
Study Locations (14)
New York
- Roswell Park Cancer Institute - Buffalo
- Weill Cornell Medical College - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
- The Ohio State University - Columbus
Arizona
- Mayo Clinic - Scottsdale
California
- Stanford University - Stanford
Florida
- H. Lee Moffitt Cancer Center - Tampa
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- University of Minnesota - Minneapolis
Missouri
- Washington University St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 911 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206309
The ClinicalTrials.gov registry entry for NCT01206309 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 911 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 113-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (706% higher). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01206309 reports 14 study locations spanning 12 distinct geographic areas - top geographies include New York, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT01206309 about?
NCT01206309 is a clinical study titled "Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation". The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
What is the current status of trial NCT01206309?
This trial is currently completed. The enrollment target is 911 participants. The study started on 2011-03. Estimated completion is 2016-10.
What conditions does trial NCT01206309 study?
This clinical trial studies the following conditions: Graft Vs Host Disease, Bronchiolitis Obliterans, Cutaneous Sclerosis.
Who is sponsoring clinical trial NCT01206309?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01206309 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.